Chongqing Zhifei Biological Products Co., Ltd. Share Price
Equities
300122
CNE100000V20
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 20.10 CNY | +0.70% |
|
-2.24% | -23.57% |
| 11-12 | Chongqing Zhifei Biological Products Subsidiary Gets China Nod for Shingles, Chickenpox Vaccine | MT |
| 10-29 | Zhifei biological products' Q3 net loss at 601.1 million yuan | RE |
| Capitalization | 48.12B 6.81B 5.85B 5.48B 5.11B 9.43B 612B 10.26B 64.1B 24.75B 289B 25.54B 25B 1,058B | P/E ratio 2025 * |
-26.6x | P/E ratio 2026 * | 38.9x |
|---|---|---|---|---|---|
| Enterprise value | 43.55B 6.16B 5.3B 4.96B 4.62B 8.54B 554B 9.29B 58.02B 22.4B 262B 23.12B 22.63B 957B | EV / Sales 2025 * |
4.1x | EV / Sales 2026 * | 2.4x |
| Free-Float |
14.76% | Yield 2025 * |
-
| Yield 2026 * | 0.55% |
| 1 day | +0.70% | ||
| 1 week | -2.24% | ||
| Current month | -2.24% | ||
| 1 month | -3.37% | ||
| 3 months | -8.43% | ||
| 6 months | +3.08% | ||
| Current year | -23.57% |
| 1 week | 19.7 |  | 20.69 |
| 1 month | 19.7 | | 22.18 |
| Current year | 18.7 | | 27.8 |
| 1 year | 18.7 | | 31.4 |
| 3 years | 18.7 | | 72.71 |
| 5 years | 18.7 | | 154.13 |
| 10 years | 7.17 | | 154.13 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhen Jing Li
DFI | Director of Finance/CFO | 43 | 18/08/2015 |
Ren Sheng Jiang
PSD | President | 72 | 16/08/2009 |
Jie Xun
PRN | Corporate Officer/Principal | 36 | 31/12/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Ren Sheng Jiang
CHM | Chairman | 72 | 16/08/2009 |
Ling Feng Jiang
BRD | Director/Board Member | 45 | 09/08/2018 |
Zhen Jing Li
BRD | Director/Board Member | 43 | 09/04/2018 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.70% | -2.24% | -33.69% | -64.82% | 6.81B | |
| -0.61% | -7.92% | -7.67% | -3.89% | 73.7B | |
| -0.81% | -1.18% | -34.44% | -38.79% | 58.94B | |
| +3.17% | +2.91% | +33.57% | +247.91% | 54.7B | |
| -2.32% | +64.10% | +64.10% | +64.10% | 51.57B | |
| -0.37% | -0.43% | +14.91% | -37.80% | 26.6B | |
| -1.66% | -2.23% | +143.39% | +224.51% | 20.25B | |
| +2.05% | -1.86% | +35.04% | +24.21% | 20.13B | |
| -12.04% | -14.35% | +49.18% | +1,058.63% | 16.58B | |
| -1.50% | +2.26% | +155.78% | +687.59% | 14.19B | |
| Average | -1.34% | -2.70% | +42.02% | +216.16% | 34.35B | |
| Weighted average by Cap. | -0.75% | -2.50% | +27.22% | +131.56% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 10.62B 1.5B 1.29B 1.21B 1.13B 2.08B 135B 2.27B 14.15B 5.46B 63.87B 5.64B 5.52B 234B | 16.35B 2.31B 1.99B 1.86B 1.74B 3.21B 208B 3.49B 21.79B 8.41B 98.33B 8.68B 8.5B 360B |
| Net income | -1.81B -256M -220M -206M -192M -355M -23.05B -386M -2.41B -931M -10.89B -961M -941M -39.81B | 762M 108M 92.66M 86.8M 80.91M 149M 9.7B 163M 1.02B 392M 4.58B 405M 396M 16.75B |
| Net Debt | -4.56B -645M -555M -520M -484M -895M -58.09B -973M -6.08B -2.35B -27.44B -2.42B -2.37B -100B | -8.94B -1.26B -1.09B -1.02B -949M -1.75B -114B -1.91B -11.91B -4.6B -53.74B -4.75B -4.64B -196B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 20.10 ¥ | +0.70% | 13,378,540 |
| 04/12/25 | 19.96 ¥ | -0.25% | 11,524,750 |
| 03/12/25 | 20.01 ¥ | -0.79% | 11,853,050 |
| 02/12/25 | 20.17 ¥ | -1.90% | 14,740,940 |
| 01/12/25 | 20.56 ¥ | 0.00% | 11,668,470 |
End-of-day quote Shenzhen S.E., December 04, 2025
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 300122 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition